CD44 Gene Polymorphisms on Hepatocellular Carcinoma Susceptibility and Clinicopathologic Features
Table 3
Adjusted odds ratio (AOR) and 95% confidence interval (CI) of clinical status and CD44 rs187115 genotypic frequencies in 203 HCC patients.
Variable
Genotypic frequencies
AA ()
AG+GG ()
OR (95% CI)
AOR (95% CI)
(%)
(%)
Clinical stage
Stage I/II
81 (65.9%)
46 (57.5%)
1.00
1.00
Stage III/IV
42 (34.1%)
34 (42.5%)
1.425 (0.799–2.544)
1.754 (0.818–3.760)
Tumor size
≦T2
81 (65.9%)
48 (60.0%)
1.00
1.00
>T2
42 (34.1%)
32 (40.0%)
1.286 (0.718–2.301)
1.375 (0.639–2.960)
Lymph node metastasis
No
120 (97.6%)
74 (92.5%)
1.00
1.00
Yes
3 (2.4%)
6 (7.5%)
3.243 (0.787–13.362)
5.024 (0.892–28.309)
Distant metastasis
No
118 (95.9%)
74 (92.5%)
1.00
1.00
Yes
5 (4.1%)
6 (7.5%)
1.914 (0.564–6.494)
3.360 (0.600–18.226)
The Child-Pugh grade
A
89 (72.4%)
58 (72.5%)
1.00
1.00
B or C
34 (27.6%)
22 (27.5%)
0.993 (0.529–1.864)
1.208 (0.534–2.731)
HBsAg
Negative
73 (59.3%)
46 (57.5%)
1.00
1.00
Positive
50 (40.7%)
34 (42.5%)
1.079 (0.610–1.910)
1.153 (0.538–2.471)
Anti-HCV
Negative
67 (54.5%)
40 (50.0%)
1.00
1.00
Positive
56 (45.5%)
40 (50.0%)
1.196 (0.681–2.103)
1.075 (0.526–2.198)
Liver cirrhosis
Negative
30 (24.4%)
26 (32.5%)
1.00
1.00
Positive
93 (75.6%)
54 (67.5%)
0.670 (0.359–1.249)
0.500 (0.220–1.133)
The ORs analyzed by their 95% CIs were estimated by logistic regression models. The AORs with their 95% CI were estimated by multiple logistic regression models, after controlling for age, gender, and tobacco and alcohol consumption. >T2: multiple tumor more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s).
